Scientists at USC Michelson Center for Convergent Bioscience and Japan’s Nagoya University find and test a promising drug that stops cancer by interfering with the cancer cells’ metabolism and other circadian-related functions
A new drug shows potential to halt cancer cells’ growth by stunting the cells’ biological clock.
The findings from scientists at the USC Michelson Center for Convergent Bioscience and Nagoya University’s Institute of Transformative BioMolecules (ITbM) advance a burgeoning area of research: turning the body’s circadian rhythms against cancer.
Their study, conducted on human kidney cancer cells and on acute myeloid leukemia in mice, was published Jan. 23 in the journal Science Advances.
Scientists know that disrupting sleep and other elements of humans’ circadian rhythm can harm health. The same is true for the circadian clock of cells themselves. If researchers could disturb the circadian clock of cancer cells, they theorize, they could potentially hurt or kill those cells.
The scientists found that a molecule named GO289 targets an enzyme that controls the cell’s circadian rhythm. This drug-protein interaction then disrupts the functions of four other proteins that are important for cell growth and survival.
Human bone cancer cells stopped growing when a drug molecule jammed their circadian rhythm during a study that appears in Science Advances. Photo courtesy of the Kay lab at the USC Michelson Center for Convergent Bioscience.
In effect, GO289 can jam the cogs of the cell’s circadian clock, slowing its cycles. And it can do so with little impact to healthy cells.
“In some cancers, the disease takes over the circadian clock mechanism and uses it for the evil purpose of helping itself grow,” said Steve Kay, director of convergent biosciences at the USC Michelson Center and USC Provost Professor of Neurology, Biomedical Engineering and Biological Sciences. “With GO289, we can interfere with those processes and stop the cancer from growing.”
Kay is among several scientists from USC Dornsife College of Letters, Arts and Sciences, USC Viterbi School of Engineering and Keck School of Medicine of USC who are collaborating across multiple disciplines to find new solutions for treating cancer, neurological disease and cardiovascular disease.
Finding the right candidate
On its initial interactions with human bone cancer cells, GO289 appeared to slow the tumors’ circadian clock as it targeted an enzyme, named CK2.
To see if GO289 consistently hindered other cancers in the same way, the scientists then tested it on human kidney cancer cells and on mice with acute myeloid leukemia. They found that GO289 specifically affected cancer cell metabolism and other circadian-related functions that normally would enable the cancer to grow and spread.
Kay is optimistic about the findings. “This could become an effective new weapon that kills cancer,” he said.
The Latest on: Cancer
[google_news title=”” keyword=”cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer
- Rheumatoid Arthritis Is No Bar to Cancer Immunotherapyon November 13, 2019 at 1:17 pm
Some cancer cells exploit these molecules to dial down immune attacks that would otherwise kill them; the checkpoint inhibitors restore the immune activity, producing a highly potent anti-cancer ...
- Teva Pharmaceuticals To Resume Production Of Scarce Childhood Cancer Drug Vincristineon November 13, 2019 at 12:24 pm
Teva pharmaceuticals has announced it is resuming production of vincristine after shortages resulted ... [+] in children with cancer missing doses of the vital drug. Getty Pharmaceutical company Teva ...
- Discovery: New biomarker for cancer stem cellson November 13, 2019 at 12:23 pm
In the world of cancer biology, not all biomarkers are created equal. These molecules that alert doctors that an abnormal process may be underway can appear as an array of aberrant proteins ...
- ESMO Breast Cancer Roundtable: Episode 5on November 13, 2019 at 11:48 am
At the recent ESMO Congress 2019 in Barcelona, Hope Rugo, MD, Jennifer Litton, MD, and Michelle Melisko, MD, gathered to discuss new and potentially practice-changing data from the meeting on advanced ...
- Justice Ruth Bader Ginsburg, a four-time cancer survivor, misses oral argument with stomach bugon November 13, 2019 at 10:30 am
WASHINGTON – Supreme Court Associate Justice Ruth Bader Ginsburg missed oral argument Wednesday due to a stomach illness, less than three months after completing treatment for her fourth bout with ...
- U.S. states can do more to prevent, treat lung canceron November 13, 2019 at 10:23 am
(HealthDay)—States can do more to prevent and treat lung cancer, according to a report published online Nov. 13 by the American Lung Association. Researchers provided a state-specific description of ...
- CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cellson November 13, 2019 at 10:07 am
The present study demonstrates that carbonic anhydrase IX (CAIX), one of the major acid/base regulators in cancer cells, forms a protein complex with MCT1 and MCT4 in tissue samples from human breast ...
- A view on drug resistance in canceron November 13, 2019 at 10:05 am
The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and ...
- Have you experienced sexual difficulties after breast cancer treatment?on November 13, 2019 at 9:49 am
A new survey has revealed that nearly half of women diagnosed with breast cancer have experienced sexual difficulties as a result of treatment. According to the study, 46% of women have experienced ...
- Heart attack survivors at greater risk for developing canceron November 13, 2019 at 9:18 am
Here's some worrisome news for folks who manage to survive a heart attack: New research suggests they might be far more vulnerable to developing cancer down the road. People who suffered a heart ...
via Bing News